Ketamine Infusion Therapy for Australian Veterans with Treatment Resistant Depression and Post-Traumatic Stress Disorder

This open-label, interventional trial (n=100) will investigate the effects of ketamine infusion therapy on Australian veterans with treatment-resistant depression (TRD) and post-traumatic stress disorder (PTSD). Participants will receive six initial intravenous ketamine infusions over two weeks (35–70mg/70kg per session), followed by up to six maintenance infusions every three to six weeks based on individual response.

The study, conducted by Zed3 Medical Group and the University of Queensland, aims to establish an evidence base for ketamine as a treatment for veterans with TRD and PTSD. It will assess changes in depression and PTSD symptoms, as well as suicidality and recovery, using standard psychological scales. Infusions will be administered in a hospital setting under the supervision of anaesthetists, with ongoing monitoring by nurses. Recruitment is expected to begin in February 2025 across multiple Australian states.

Topic Depression Treatment-Resistant Depression PTSD Suicidality
Compound Ketamine
Country Australia
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.